Relation between cognitive dysfunction and reduced vital capacity in amyotrophic lateral sclerosis

Author(s): Kim SM, Lee KM, Jong YH, Park KS, Yang JH, et al.

Abstract

Background: Many patients with amyotrophic lateral sclerosis (ALS) with cognitive impairment have fronto-temporal dysfunction. Whereas in some patients with ALS the fronto-temporal dysfunction is undoubtedly due to the degenerative process associated with the disease, in others dysfunction cannot be accounted for by an irreversible degenerative process alone, as it also appears to involve a reversible process. We hypothesised that reduced vital capacity can be a key contributor to the fronto-temporal dysfunction observed in patients with ALS.

Objective: To investigate the association between fronto-temporal dysfunction and reduced vital capacity in ALS.

Methods: 16 consecutive patients who conformed to a diagnosis of definite or probable ALS (El escorial criteria) were grouped by vital capacity, and their clinical characteristics and cognitive functions, including disease duration, attention, executive function and memory, were measured.

Results: Patients with a reduced vital capacity performed significantly poorer in memory retention (p = 0.028), retrieval efficacy (p = 0.003), spoken verbal fluency (p = 0.03) and spoken verbal fluency indexes (p = 0.016) than those with a normal vital capacity.

Conclusion: The fronto-temporal dysfunction in ALS might be attributable to potentially reversible secondary effects associated with reduced vital capacity, as well as to the primary degenerative process.

Similar Articles

Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease

Author(s): Lattante S, Conte A, Zollino M, Luigetti M, Del Grande A, et al.

Amyotrophic Lateral Sclerosis – Frontotemporal Spectrum Disorder (ALS-FTSD): Revised diagnostic criteria

Author(s): Strong MJ, Abrahams S, Goldstein LH, Wooley S, Mclaughlin P, et al.

Genetic counselling in ALS: facts, uncertainties and clinical suggestions

Author(s): Chiò A, Battistini S, Calvo A, Caponnetto C, Conforti FL, et al.

New ALS-Related Genes Expand the Spectrum Paradigm of Amyotrophic Lateral Sclerosis

Author(s): Sabatelli M, Marangi G, Conte A, Tasca G, Zollino M, et al.

ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosis

Author(s): Lattante S, Pomponi MG, Conte A, Marangi G, Bisogni G, et al.

Pathological laughing and crying in amyotrophic lateral sclerosis

Author(s): McCullagh S, Moore M, Gawel M, Feinstein A

The El Escorial criteria: strengths and weakessnes

Author(s): Agosta F, Al-Chalabi A, Filippi M, Hairdman O, Kaji R, et al.

Cognitive changes predict functional decline in ALS: a polupaltion-based longitudinal study

Author(s): Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, et al.

Cognitive functioning in sporadic amyotrophic lateral sclerosis: A six month longitudinal study

Author(s): Robinson KM, Lacey SC, Grugan P, Glosser G, Grossman M, et al.

Premorbid personality characteristics of patients with ALS

Author(s): Grossman AB, Bonnie EL, Bradley WG

Emotional Adjustment in Amyotrophic Lateral Sclerosis (ALS)

Author(s): Lulè D, Paulì S, Altinas E, Singer U, Mèrk T, et al.

Prevalence of Fatigue and depression in ALS patients and change over time

Author(s): McElhiney MC, Rabkin JC, Gordon PH, Goetz R, Mitsumoto H

Deficits in emotional and social cognition in Amyotrophic Lateral Sclerosis

Author(s): Girardi A, MacPherson SE, Abrahams S

Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum

Author(s): Lillo P, Savage S, Mioshui E, Kiernan MC, Hodges JR

La diagnosi in psichiatria

Author(s): Frances A

The cognitive profiles of ALS: A systematic review and meta-analisis update

Author(s): Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, et al.

Functional scales and motor assessment in Amyotrophic Lateral Sclerosis

Author(s): Benaim C, Desnuelle C, Fourniere-Mehouas M

The Amyotrophic Lateral Sclerosis Functional Rating Scale

Author(s): ALS CNTF Treatment Study (ACTS) Phase I-II Study Group

The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS)

Author(s): Poletti B, Solca F, Carelli L, Madotto F, Lafronza A, et al.